Featured Publications
Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
Colavito SA, Platt JT, Held MA, Liu Z, Sokup R, Stern DF. Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer. Oncotarget 2019, 10: 4822-4839. PMID: 31448050, PMCID: PMC6690678, DOI: 10.18632/oncotarget.27104.Peer-Reviewed Original ResearchBreast cancerDrug combinationsB-cell lymphoma-2 inhibitorTriple-negative breast cancerEffective treatment strategiesBreast cancer cellsEffective drug combinationsCombination regimenPoor prognosisCombination therapyTreatment optionsTreatment strategiesBCL2 inhibitorsEffective treatmentSelf-renewal capabilityCancerTumor cellsDifferent dosesCancer cellsMammary cellsCheckpoint kinase 1 inhibitorsKinase 1 inhibitorMesenchymal characteristicsMesenchymal transformationUntreated cells
2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget 2015, 6: 37410-37425. PMID: 26485762, PMCID: PMC4741938, DOI: 10.18632/oncotarget.6138.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisApoptosis Regulatory ProteinsAzepinesAzocinesBenzhydryl CompoundsCamptothecinCell Line, TumorCell ProliferationDocetaxelDose-Response Relationship, DrugDrug SynergismFemaleHumansIrinotecanLung NeoplasmsMice, Inbred BALB CMice, NudeNF-kappa BPaclitaxelSignal TransductionTaxoidsTime FactorsTopoisomerase InhibitorsTriazolesTumor BurdenXenograft Model Antitumor AssaysConceptsLung adenocarcinoma cellsDebio 1143Adenocarcinoma cellsOngoing clinical trialsNon-canonical NF-κB signalingTopoisomerase inhibitorsLung adenocarcinoma xenograftsNF-κB signalingBromodomain inhibitor JQ1Clinical trialsConventional chemotherapyTumor volumeVivo treatmentAdenocarcinoma xenograftsAnti-apoptotic proteinsSingle agentCaspase-8 expressionVivo growthInhibitor JQ1Tumor cellsPro-apoptotic protein SmacJQ1Cell linesInhibitorsTaxanes
2009
Molecular Classification of Normal and Cancer Mammospheres.
Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.Peer-Reviewed Original ResearchCancer stem cellsPrimary tumorBreast cancerTumor cellsStem cellsAbsence of CD24Breast cancer specimensHuman breast cancerFine-needle aspirationNormal breast tissueExpression of CD44Tumor tissue samplesPutative stem cell markersCD44-positive cellsKey protein markersEx vivo cultureStem cell markersNovel drug targetsSpecific therapyTreatment successNeedle aspirationCancer specimensMyoepithelial markersBT-20Positive cells
1985
Type beta transforming growth factor: a bifunctional regulator of cellular growth.
Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proceedings Of The National Academy Of Sciences Of The United States Of America 1985, 82: 119-123. PMID: 3871521, PMCID: PMC396983, DOI: 10.1073/pnas.82.1.119.Peer-Reviewed Original ResearchConceptsGrowth factorEpidermal growth factorColony formationAnchorage-independent growthNRK fibroblastsType betaPlatelet-derived growth factorHuman lung carcinoma cellsLung carcinoma cellsBreast carcinoma cell linesCarcinoma cell linesCellular myc geneLung carcinomaHuman tumor cellsHuman melanomaAnchorage-dependent growthHuman placentaTumor cellsCarcinoma cellsCell cycle timeHuman plateletsCell linesSoft agarTwo-chain polypeptideBifunctional regulator